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Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy
for noninvasive identification of mutations across multiple genetic loci and
for disease monitoring in melanoma. In this study, we compared the muta-
tion profiles of tumor biopsies and plasma ctDNA from metastatic
melanoma patients using custom sequencing panels targeting 30 mela-
noma-associated genes. Somatic mutations were identified in 20 of 24
melanoma biopsies, and 16 of 20 (70%) matched-patient plasmas had
detectable ctDNA. In a subgroup of seven patients for whom matching
tumor tissue and plasma were sequenced, 80% of the mutations found in
tumor tissue were also detected in ctDNA. However, TERT promoter
mutations were only detected by ddPCR, and promoter mutations were
consistently found at lower concentrations than other driver mutations in
longitudinal samples. In vitro experiments revealed that mutations in pro-
moter regions of TERT and DPH3 are underrepresented in ctDNA. While
the results underscore the utility of using ctDNA as an alternative to tissue
biopsy for genetic profiling and surveillance of the disease, our study high-
lights the underrepresentation of promoter mutations in ctDNA and its
potential impact on quantitative liquid biopsy applications.
1. Introduction
The use of targeted therapeutic agents and immune
checkpoint inhibitors has improved the survival of
metastatic melanoma patients in recent years (Luke
et al., 2017). Current treatment strategies employ vari-
ous systemic agents, often used in succession, that are
dependent on the genetic landscape of the tumor
(Ascierto et al., 2013; Chen et al., 2016; Larkin et al.,
2014; Luke et al., 2017; Ribas et al., 2015; Santiago-
Abbreviations
cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; ddPCR, digital droplet PCR; FDG-PET/CT, 18F-labeled fluorodeoxyglucose positron
emission tomography/computed tomography; FFPE, formalin-fixed paraffin embedded tissue; MTB, metabolic tumor burden; NGS, next-
generation sequencing.
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Walker et al., 2016). Treating physicians are con-
fronted with new challenges, such as stratifying
patients for appropriate treatments and monitoring
long-term responders for progression. Consequently,
reliable methods for monitoring disease progression
and treatment response or resistance are necessary.
Circulating tumor DNA (ctDNA), which is shed
into the blood as a result of tumor cell apoptosis and
necrosis, has been shown to have potential clinical util-
ity for molecular classification (Haselmann et al.,
2018), prognostication (Ascierto et al., 2013; Gray
et al., 2015; Knol et al., 2016; Sanmamed et al., 2015),
and monitoring patient response to therapy (Girotti
et al., 2016; Gray et al., 2015; Lee et al., 2017;
Schreuer et al., 2016; Wong et al., 2017) in melanoma.
Plasma ctDNA has also been shown to capture clonal
evolution, via identification of mutations that mediate
resistance to BRAF inhibitors (Girotti et al., 2016;
Gray et al., 2015). Moreover, the analysis of plasma
and multiple metastatic deposits in two melanoma
patients indicated that ctDNA can reflect the genetic
heterogeneity of various subclones across multiple
tumors (Wong et al., 2017). Thus, ctDNA appears to
be a useful biomarker for patient surveillance during
treatment, acting as a potential surrogate to tissue
biopsy and providing a comprehensive snapshot of the
molecular diversity of metastases. Nevertheless, the
detection rate of ctDNA in melanoma patients and
concordance of mutations between plasma and tissue
still requires further study, especially beyond detection
of BRAF mutations (Calapre et al., 2017).
Based on their somatic mutation profiles, melanomas
can be divided into four genomic subtypes: BRAF,
RAS (N/H/K), NF1, and triple wild-type (WT)
(TCGA, 2015). Recurring hotspot mutations in the
V600 codon of BRAF or Q61 codon of NRAS are the
most prevalent and occur in approximately 35–50%
and 10–25% of melanomas, respectively (Pollock et al.,
2002; TCGA, 2015; Tsao et al., 2012). Most ctDNA
studies thus far have only analyzed BRAF mutant cases
(Ascierto et al., 2013; Girotti et al., 2016; Gray et al.,
2015; Knol et al., 2016; Schreuer et al., 2016). These
studies have remarked on the high fidelity of BRAF
mutant ctDNA to reflect disease burden and tumor sta-
tus of patients prior to and during treatment (Ascierto
et al., 2013; Girotti et al., 2016; Gray et al., 2015; Knol
et al., 2016; Schreuer et al., 2016). However, it is
imperative to ascertain the detection rate and kinetics
of other common melanoma-associated mutations to
determine whether they can be effectively used for
patient surveillance, particularly in BRAF WT cases.
In this study, we identified tumor mutations using a
custom next-generation sequencing (NGS) panel
targeting melanoma-specific genes in a cohort of meta-
static melanoma patients and determined the detection
rate of ctDNA by targeting mutations identified in
each patient’s tumor. We performed sequencing of a
set of paired melanoma tissue biopsies and circulating
free DNA (cfDNA) to determine the level of concor-
dance of mutations across these two compartments.
Furthermore, we evaluated the suitability of various
mutated loci for monitoring ctDNA in patients under-
going systemic therapies. Finally, we performed
in vitro experiments to evaluate whether mutations in
promoter regions are underrepresented in cfDNA.
2. Materials and methods
2.1. Patients
Metastatic melanoma patients were enrolled in the study
between 2013 and 2016 at Sir Charles Gairdner Hospital
(SCGH) and Fiona Stanley Hospital (FSH) in Perth,
Western Australia. Written informed consent was
obtained from all patients under approved Human
Research Ethics Committee protocols from Edith Cowan
University (No. 11543) and Sir Charles Gairdner Hospi-
tal (No. 2007-123). The study methodologies conformed
to the standards set by the Declaration of Helsinki.
2.2. Tissue analysis
Tissue biopsies were retrospectively tested for mutation
profile. The tissue biopsies were included if obtained prior
to therapy initiation, with no systemic treatment during
that period. Hematoxylin and eosin (H&E)-stained sec-
tions were assessed by a pathologist and the percentage
of tumor cells estimated. Microdissection was performed
when the neoplastic cell content was below 50%. DNA
was isolated using QIAamp Tissue FFPE Kits (Qiagen,
Hilden, Germany) as per the manufacturer’s instructions.
FFPE gDNA was stored at 4 °C until processed for tar-
geted NGS (Supporting Information).
2.3. Plasma sample preparation and cfDNA
extractions
Blood samples were collected prior to initiation of treat-
ment into EDTA vacutainer or Cell-Free DNA BCT
(Streck, La Vista, NE, USA) tubes and stored at 4 °C.
Plasma was separated within 24 h by centrifugation at
300 g for 20 min, followed by a second centrifugation at
4700 g for 10 min and then stored at 80 °C until
extraction. cfDNA was isolated from 1 to 5 mL of
plasma using QIAamp Circulating Nucleic Acid Kits
(Qiagen, Hilden, Germany) as per the manufacturer’s
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instructions. cfDNA was eluted in 40 ll AVE buffer
(Qiagen, Hilden, Germany) and stored at 80 °C until
ctDNA quantification by droplet digital PCR (ddPCR)
(Supporting Information) or processed for sequencing
using a QIASeq Targeted DNA Custom Panel (CDHS-
12967Z-1243) (Supporting Information).
2.4. Metabolic tumor burden analysis
18F-labeled fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT)
scans were performed on combined PET/CT scanners
at approved nuclear radiology centers in Perth, Wes-
tern Australia. After a minimum fasting period of 6 h,
patients were injected with 5 MBq pr. kg 10% of
18FDG (minimum 200 MBq and maximum 600 MBq).
PET was performed on patients with serum glucose
levels below 11 nmolL1 at an acquisition time of
3 min per bed position. To determine anatomical loca-
tion and for attenuation correction purposes, a whole-
body low-dose computed tomography scan was
performed. All images were reviewed retrospectively
and independently by an experienced nuclear medicine
physician, blinded to the ctDNA analysis. Analysis
was conducted on a Siemens Syngo via workstation
(Siemens Healthcare GMbH, Erlangen, Germany)
reporting the global total lesion glycolysis (TLG),
which combines volumetric and metabolic information
(Chen et al., 2012; Kim et al., 2013) and can provide a
better evaluation of Metabolic tumor burden (MTB).
2.5. Targeted amplicon sequencing and
bioinformatics of tumor tissue
Tissue biopsy mutation profiles were identified by tar-
geted NGS using a customized panel of 30 melanoma-
associated genes (Illumina, San Diego, CA, USA) with
950 amplicons and an Illumina MiSeq instrument.
Forward and reverse strand NGS libraries were pre-
pared using the customized melanoma panel according
to the manufacturer’s instructions. In brief, forward
and reverse oligonucleotide pools were hybridized to
DNA samples overnight. Hybridized samples were
then ligated, extended, and amplified with unique
index sequences (barcodes) and sequencing adaptors.
Amplified libraries were purified using Agencourt
AMPure XP magnetic beads (Beckman Coulter, Brea,
CA, USA), first at a ratio of 1 (library):1 (beads), as
per the manufacturer’s protocol, followed by a second
round of purification at a library to bead ratio of
1.25 : 1. Library DNA concentrations were quantified
using a Qubit 3.0 fluorometer. Libraries were normal-
ized to 4 nmolL1 in EBT buffer, pooled, and
sequenced on a MiSeq instrument (Illumina). Sequence
alignment and variant calling were performed by
ILLUMINA MISEQ REPORTER software (version 2.4,
Illumina). Genomic variants were annotated using the
ILLUMINA VARIANT STUDIO 2.2 software (Illumina). Vari-
ants with allele frequency (VAF) >3% and that passed
the software quality parameters were considered true
mutations. Polymorphisms and synonymous mutations
were excluded, and the minimum read depth was set at
500. The polyPhen score, which represent the probabil-
ity of the impact of an amino acid substitution on the
protein structure and function, was indicated for each
variant.
2.6. Sequencing and bioinformatics of cfDNA
QIASeq Targeted DNA Custom Panel (CDHS-
12967Z-1243) containing the same panel of 30 mela-
noma-associated genes with similar regions of interest
was used to determine the mutational profile of a sub-
set of ctDNA samples. Isolated DNA was quantified
with Quant-iT dsDNA High-Sensitivity Assay Kits
(Life Technologies, Carlsbad, CA, USA) or Quant-iT
dsDNA BR Assay Kits (Life Technologies).
QIASeq Targeted DNA Panel Kits were used for
library generation and target enrichment. Fragment
size distribution of the libraries was determined with an
Agilent Bioanalyzer using a DNA 7500 chip (Agilent
Technologies, Santa Clara, CA, USA). Library quan-
tification was performed using a KAPA Library Quan-
tification Kit for Illumina Platforms (Roche, Basel,
Switzerland). Indexed sample libraries were equimo-
larly pooled and sequenced on an Illumina NextSeq
sequencer using a NextSeq 500 Mid Output v2 Kit (300
cycles). Data analysis including alignment to the refer-
ence genome and variant calling was carried out using
QIAseq Target DNA online portal and INGENUITY VARI-
ANT ANALYSIS software (Qiagen, Hilden, Germany).
Concordance was defined as detecting an identical
single nucleotide variation (SNV) in plasma relative to
tissue in regions that were covered by both targeted
amplicon sequencing panels used for NGS of tissue
and plasma biopsies. Discordance was defined as
SNVs detected only in plasma or tumor tissue. Con-
cordance of SNVs found in plasma that were detect-
able in tissue by NGS (Fig. S2) was calculated for
each tissue/plasma pair using the formula:
Concordance ð%Þ ¼ ðx yÞ  100
x = number of variants confirmed in plasma and
tissue; y = total number of variants detected in
plasma.
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2.7. Droplet digital PCR
Commercially available and/or customized probes were
used to analyze ctDNA by ddPCR. Droplets were gen-
erated using an Automatic Droplet generator QX200
AutoDG (Bio-Rad, Hercules, CA). Amplifications were
performed using cycling conditions previously described
(Gray et al., 2015; McEvoy et al., 2017). For DPH3
mutation analysis, the following probe and primer
design was used: forward primer sequence: GGG CTC
GGC ATC ATC AG, reverse primer sequence: CCG
CTA CCG GTT ATC CAT TT, DPH3 c.C8T probe:
/56-FAM/TAG CTC TTC/ZEN/CGG CGC A/
3IABkFQ/, DPH3 WT probe: /5HEX/TAG CCC
TTC/ZEN/CGG CGC A/3IABkFQ/, from Integrated
DNA Technologies (Coralville, IO, USA). Primers and
probes for TERT ctDNA analysis were as previously
reported (McEvoy et al., 2017). Levels of ctDNA per
loci were defined based on the level of false-positive
droplets in at least 12 healthy controls (Table S5).
2.8. Cell culture
UACC62 cells were obtained from NCI’s Development
Therapeutics Program; 1205Lu cells were obtained from
Meehard Herlyn, The Wistar Institute; and C037 and
A07 cells were obtained from Chris Schmidt, QIMR
Berghofer Medical Research Institute. Cells were grown
in T-25 cell culture flasks and cultured in DMEM med-
ium fortified with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin. Cells were primarily seeded
at 5 x 105 cells per T25 flask and supplemented with
5 mL media. Cells were cultured for 72 h at 37 °C with
5% CO2. At the end of the incubation, the growth med-
ium was collected in 15-mL nuclease-free tubes. Super-
natant was isolated using a dual centrifugation
protocol, spinning at 300 9 g for 20 min followed by a
second spin at 4700 x g for 10 min. The samples were
then stored at 80 °C until extraction. Supernatant
cfDNA was extracted using QIAamp Circulating
Nucleic Acid Kits (Qiagen, Hilden, Germany) and then
were purified using Agentcour AMPure XP beads
(Beckman Coulter, Brea, CA, USA) primarily at 0.6 : 1
bead to eluted DNA volume ratio to separate large frag-
ment size (>700 bp). Supernatant was then transferred
to another tube and further purified at 1.6 : 1 ratio to
isolate fragments within the 100–300 bp range.
2.9. Statistics
Unpaired two-tailed t-test was used to compare the
levels of TERT and DPH3 promoter ctDNA relative
to internal exonic gene region controls from cell line
supernatant. Statistical analyses were performed using
GRAPHPAD PRISM version 5.
3. Results
3.1. Mutational profile of melanoma tumors
FFPE tumor tissue from twenty-four stage IV mela-
noma was first analyzed for somatic mutations using a
custom amplicon sequencing panel targeting 950
amplicons over 30 commonly mutated genes in mela-
noma (Table S1). Somatic mutations were identified in
20 of the samples, and four samples did not have iden-
tifiable somatic mutations within the loci analyzed
(Fig. 1). Table 1 highlights the clinical characteristics
of patients analyzed.
Six of 24 (25%) cases had mutations in BRAF p.V600
(Fig. 1). The BRAF sequence variants identified in the
tumors (N = 6) via sequencing were an exact match to
the variant annotated in the archival pathology reports.
The uveal melanoma case (MM270) included in the
study had a GNAQ p.Q209L mutation, which is com-
monly found in this melanoma subtype (Robertson
et al., 2018). We also observed a high frequency of
patients with deleterious mutations (polyPhen score
>0.7) in GRM3 (38%), TERT promoter (33%), NRAS
(25%), NF1 (21%), and TP53 (21%) (Fig. 1, Table S2).
In patients with TERT promoter and NRAS mutations,
the variants were found in the hotspot positions of the
promoter region (C250T/C228T) and codon 61 (p.Q61),
respectively. There were also high numbers of patients
with variants in MECOM (33%), ARID1B (25%),
and PIK3CA (21%), but the polyPhen scores indicated
benign or tolerable effects on protein function.
Five of the 24 patients analyzed harbored cosmic-
annotated mutations in TP53: p.R248W, p.R248Q,
p.S127F, p.S46F, and p.G266R. GRM3 and NF1 were
mutated at 38% and 21%, respectively, with mutations
distributed along the gene coding regions, consistent
with their tumor suppressor nature. Four of the muta-
tions in these genes, GRM3 p.D548N, GRM3
p.R668H, NF1 p.W336T, and NF1 p.P1851S, have
been reported previously in COSMIC and/or TCGA
studies of melanoma (TCGA, 2015). In line with previ-
ous reports (Cirenajwis et al., 2017; TCGA, 2015),
patients bearing NF1 mutations had higher median
mutational burden compared to other patients in this
cohort (P = 0.019) (Fig. S1). The majority of muta-
tions in these genes were not previously described, but
their polyPhen scores indicate that the changes should
have deleterious effects (Table S2).
Overall, our custom sequencing panel targeting com-
monly mutated genes in melanoma was effective in
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providing mutational information in most patients,
allowing for identification of targetable mutations for
ctDNA analyses in patients WT for BRAF and NRAS.
3.2. ctDNA detection in melanoma using multiple
mutational targets
Once the mutational profile of tumor tissues was iden-
tified, we screened the matching plasma samples of
patients for the presence of the identified mutations in
ctDNA using ddPCR. The length of time between tis-
sue biopsy and blood collection was indicated in
Table S4. The selection of mutational targets for
ctDNA analysis was based on the following criteria:
(a) known melanoma hotspot mutation in BRAF,
NRAS, and/or TERT promoter; (b) COSMIC/TCGA
reported mutation; (c) other mutation with a polyPhen
score >0.7 and high variant allele frequency (VAF) in
the tumor.
Analysis of plasma ctDNA showed that 14 of 20
(70%) patients with mutational data had detectable
ctDNA at baseline (Table 2). In cases where two
mutational targets were analyzed (N = 13), both muta-
tions were found either present or absent in the
ctDNA of patients, with the exception of MM362
where the TERT promoter mutation was not detect-
able in plasma. Interestingly, patients with readily
detectable ctDNA were found to have multiple metas-
tases distributed at various body sites including liver,
lungs, and bones (Table 2). In contrast, patients that
were ctDNA negative at baseline were found to pre-
dominantly have lymph node metastases, with the
exception of MM372 which had a single lung metasta-
sis and exclusion of patient MM270 (uveal melanoma).
3.3. Concordance of mutations in tissue and
plasma
Concordance of mutations in tissue and plasma was
then further analyzed in 7 of the patients who had
detectable ctDNA and sufficient plasma available
(Table 2). The mutation profile of these plasma
Fig. 1. Mutational profiles of 24 FFPE melanoma tumors assessed using a custom targeted sequencing panel. The percentage of patients
with alterations per gene are noted under frequency.
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samples was determined using a custom sequencing
panel, targeting the same loci as the panel used to ana-
lyze FFPE tumor tissues but incorporating molecular
unique identifiers to enable the detection of low fre-
quency mutations in plasma ctDNA (Table S3).
On average, 89% (range 75–100%) of SNVs found
in the plasma of patients by targeted sequencing were
also detected in the tumor tissue (Fig. S2). Only three
mutations found in plasma were not identified in the
matching tumor (Table 3). If mutations that were in
the tissue but not in plasma are included in the con-
cordance evaluation, that is, the number of overlap-
ping SNVs relative to the overall number of plasma
plus tissue mutations, average concordance is reduced
to 67%, with a range of 30–100% (Table 3 and
Fig. S2). In particular, TERT promoter mutations
were not detected in plasma by NGS, but detected by
ddPCR in four of the five discordant cases (Table 2).
The TERT promoter region is difficult to amplify due
to its high GC content, and the mutant reads from this
locus were below threshold in the NGS analysis. If
positivity by ddPCR is included in the concordance
analysis between mutations found in plasma and tis-
sues, the overall concordance between plasma and tis-
sue biopsies is 80% (range 40–100%).
The major contributor to discordance was case
MM080, with 5 SNVs found in tumor but not in plasma.
In this case, there was a 3-year gap between tissue and
blood sampling, and thus, the high number of mutations
found only in the tumor is possibly the result of clonal
evolution. Overall, these data indicate that ctDNA is
readily detectable in stage IV melanoma patients with
multiple metastatic sites. The high detection rate of
tumor-associated mutations in plasma prior to treatment
further reinforces the utility of ctDNA for genetic profil-
ing as a potential surrogate for solid tumor biopsy.
3.4. ctDNA monitoring of melanoma patients
using single or multiple mutational targets
To investigate the utility of ctDNA as a surveillance bio-
marker in melanoma patients undergoing systemic ther-
apy, patients were monitored longitudinally for ctDNA
via ddPCR targeting multiple mutations using the selec-
tion criteria described above. In the case of MM312, who
presented with isolated nodal disease in the groin, NRAS
p.Q61R mutation was undetectable in plasma ctDNA at
baseline but became detectable upon further progression
of disease (PD) (Fig. 2). Nonetheless, ctDNA was only
detectable when MTB had almost doubled at week 90,
suggesting a potential effect of MTB on ctDNA detec-
tion. No decrease in ctDNA was observed in this patient
at week 132 after commencing ipilimumab/nivolumab
therapy, but a significant decline in ctDNA was observed
at week 141. Of note, the TERT promoter mutation was
undetectable in all but one of the plasma collections.
When two or more mutations were tracked during
treatment, the ctDNA kinetics of these mutations
showed overlapping or parallel curves that were similarly
consistent with clinical response (Fig. 2), irrespective of
whether they were bona fide melanoma drivers (BRAF,
NRAS, and/or TERT) or rare deleterious mutations in
melanoma (TP53 p.R248Q, FLT1 p.T543I, KIT
p.L576P). In general, changes in ctDNA levels corre-
sponded with the changes in MTB of patients during
treatment (Fig. 2). For example, patient MM475
(Fig. 2) had multiple recognized melanoma driver muta-
tions including BRAF p.V600R, RAC1 p.P29S,
MAP2K1 p.P124S, TERT C228T, and DPH3 C8T. All
of these mutations decreased in concordance with
response to BRAF andMAPK inhibition and correlated
with a declining MTB. The concentration of all five
mutations greatly increased in plasma at week 23, corre-
sponding to a small increase in MTB. At progression
(week 24), BRAF p. V600R was at 10-fold higher concen-
tration than RAC1 andMAPK2 mutations, suggesting a
gain in copy number, which is a common mechanism of
resistance to BRAF inhibition (Johnson et al., 2015).
Table 1. Characteristics of melanoma patients with tissue and
ctDNA mutational data.
N Percentage
Melanoma type
Cutaneous 23 96
Uveal 1 4
Age
30–50 2 8
51–70 12 50
71–80 10 42
Sex
Female 5 21
Male 19 79
M classification
M1a 6 25
M1b 6 25
M1c 10 42
M1d 2 8
BRAF status
BRAF Mutant 6 25
BRAF wild-type 18 75
Mutational profiling
Mutation found 20 83
No mutation found 4 17
ctDNA detection at baseline
Positive 14 58
Negative 6 25
Not tested 4 17
176 Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Concordance of melanoma mutational landscape in tissue and ctDNA L. Calapre et al.
T
a
b
le
2
.
L
e
v
e
ls
o
f
c
tD
N
A
a
t
b
a
s
e
lin
e
a
n
d
th
e
d
is
tr
ib
u
ti
o
n
o
f
m
e
la
n
o
m
a
m
e
ta
s
ta
s
is
a
c
ro
s
s
b
o
d
y
s
it
e
s
.
P
a
ti
e
n
t
M
u
ta
ti
o
n
T
is
s
u
e
c
tD
N
A
M
u
ta
ti
o
n
T
is
s
u
e
c
tD
N
A
S
it
e
s
o
f
m
e
ta
s
ta
s
is
A
lle
lic
fr
e
q
u
e
n
c
y
(%
)
L
e
v
e
l
(c
m
L

1
)
A
lle
lic
fr
e
q
u
e
n
c
y
(%
)
A
lle
lic
fr
e
q
u
e
n
c
y
(%
)
L
e
v
e
l
(c
m
L

1
)
A
lle
lic
fr
e
q
u
e
n
c
y
(%
)
B
ra
in
B
o
n
e
L
iv
e
r
L
u
n
g
L
y
m
p
h
N
o
d
e
M
e
s
e
n
te
ry
P
a
n
c
re
a
s
P
e
lv
ic
R
e
g
io
n
S
u
b
c
u
ta
n
e
o
u
s
M
M
0
8
0
B
R
A
F
p
.V
6
0
0
K
5
8
4
3
2
8
3
8
%
T
E
R
T
C
2
5
0
T
6
6
1
0
8
0
2
0
x
x
x
M
M
3
6
4
N
R
A
S
p
.Q
6
1
K
6
3
2
0
6
4
3
4
%
x
x
x
x
x
M
M
2
2
5
B
R
A
F
p
.V
6
0
0
E
1
2
1
6
9
5
3
8
%
x
x
x
M
M
4
7
5
B
R
A
F
p
.V
6
0
0
R
4
6
3
8
0
9
%
R
A
C
1
p
.P
2
9
S
4
8
4
4
6
1
2
x
x
x
x
M
M
4
6
9
B
R
A
F
p
.V
6
0
0
E
2
4
2
3
3
8
%
x
M
M
1
8
2
B
R
A
F
p
.V
6
0
0
K
4
3
5
4
0
1
5
%
G
R
M
3
p
.P
6
0
5
S
5
4
7
2
0
1
2
x
x
x
M
M
3
6
2
N
R
A
S
p
.Q
6
1
K
8
9
3
9
0
7
%
T
E
R
T
C
2
5
0
T
4
8
0
0
x
x
x
x
x
M
M
5
5
5
N
R
A
S
p
.Q
6
1
L
4
6
9
8
4
%
T
E
R
T
C
2
5
0
T
2
4
1
6
2
x
x
x
x
M
M
5
2
2
K
IT
p
.L
5
7
6
P
2
9
5
6
4
%
T
E
R
T
C
2
2
8
T
2
3
1
1
4
x
x
x
M
M
2
8
9
T
P
5
3
p
.R
2
4
8
Q
3
6
4
8
1
%
F
L
T
1
p
.T
5
4
3
I
3
6
1
8
1
x
M
M
1
7
0
B
R
A
F
p
.V
6
0
0
E
2
6
3
3
1
%
x
x
x
M
M
3
5
8
N
R
A
S
p
.Q
6
1
K
6
1
2
2
5
%
T
P
5
3
p
.S
1
2
7
F
8
0
2
0
3
x
x
x
x
M
M
3
2
0
K
IT
p
.V
5
9
9
A
4
9
1
3
1
.2
%
D
D
X
3
X
p
.R
4
7
5
C
2
3
2
0
.1
x
x
M
M
2
3
7
N
R
A
S
p
.Q
6
1
K
2
6
4
0
.1
%
P
IK
3
C
A
p
.S
3
2
6
F
3
6
9
1
x
M
M
3
1
3
K
IT
p
.W
5
5
7
R
6
9
0
0
T
E
R
T
C
2
2
8
T
4
4
0
0
x
x
M
M
3
7
2
R
A
C
1
p
.P
2
9
S
5
9
0
0
x
M
M
3
1
2
N
R
A
S
p
.Q
6
1
R
5
0
0
0
T
E
R
T
C
2
5
0
T
3
7
0
0
x
M
M
3
3
5
C
T
N
N
B
1
p
.D
3
2
N
1
2
0
0
N
F
1
p
.P
1
8
5
1
S
2
2
0
0
x
M
M
5
5
8
T
P
5
3
p
.R
2
4
8
W
2
4
0
0
x
M
M
2
7
0
G
N
A
Q
p
.Q
2
0
9
L
2
8
0
0
x
x
x
177Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
L. Calapre et al. Concordance of melanoma mutational landscape in tissue and ctDNA
T
a
b
le
3
.
S
in
g
le
n
u
c
le
o
ti
d
e
v
a
ri
a
ti
o
n
p
ro
fi
le
d
e
ri
v
e
d
fr
o
m
N
G
S
o
f
7
m
e
la
n
o
m
a
p
a
ti
e
n
ts
w
it
h
m
a
tc
h
e
d
F
F
P
E
ti
s
s
u
e
a
n
d
p
la
s
m
a
.
M
M
0
8
0
M
M
3
5
8
M
M
3
6
2
M
M
4
6
9
M
M
4
7
5
M
M
5
2
2
M
M
5
5
5
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
c
tD
N
A
T
is
s
u
e
A
R
ID
1
B
p
.P
1
4
9
1
L
4
A
R
ID
1
B
p
.P
1
0
0
6
L
2
1
7
A
R
ID
1
B
p
.I
1
6
6
6
T
7
4
8
A
R
ID
2
p
.T
9
6
9
I
4
B
R
A
F
p
.V
6
0
0
K
2
5
5
8
B
R
A
F
p
.V
6
0
0
E
8
3
0
B
R
A
F
p
.V
6
0
0
R
8
4
6
D
D
X
3
X
p
.I
1
9
5
N
3
8
5
F
L
T
1
p
.G
7
0
6
E
3
4
F
L
T
1
p
.T
3
3
5
P
6
4
0
G
R
M
3
p
.D
5
4
8
N
4
6
1
G
R
M
3
p
.D
7
4
4
N
1
1
4
K
IT
p
.L
5
7
6
P
2
2
9
K
M
T
2
A
p
.R
1
6
3
0
Q
1
K
M
T
2
A
p
.D
2
8
9
3
E
5
M
A
P
2
K
1
p
.P
1
2
4
S
4
1
9
M
E
C
O
M
p
.S
4
1
9
F
1
5
1
5
M
E
C
O
M
p
.R
7
4
8
Q
2
2
5
M
E
C
O
M
p
.P
7
0
1
S
1
2
4
N
F
1
p
.I
1
6
2
4
L
9
1
1
N
F
1
p
.P
1
4
2
1
L
3
N
F
1
p
.L
7
9
2
F
3
2
N
R
A
S
p
.Q
6
1
K
5
6
1
7
8
9
N
R
A
S
p
.Q
6
1
L
5
4
6
R
A
C
1
p
.P
2
9
S
8
4
8
S
E
T
D
2
p
.S
9
1
7
N
4
9
T
E
R
T
C
2
2
8
T
2
a
6
0
4
a
2
3
T
E
R
T
C
2
5
0
T
2
0
a
6
6
4
8
2
a
2
4
T
P
5
3
p
.S
1
2
7
F
1
8
0
C
o
n
c
o
rd
a
n
c
e
(N
G
S
o
n
ly
)
3
0
1
0
0
6
7
7
5
8
3
6
0
6
7
C
o
n
c
o
rd
a
n
c
e
(N
G
S
+
d
d
P
C
R
)
4
0
1
0
0
6
7
7
5
1
0
0
8
0
1
0
0
B
o
x
e
s
d
e
n
o
te
fr
e
q
u
e
n
c
y
a
b
u
n
d
a
n
c
e
(%
)
o
f
e
a
c
h
S
N
V
d
e
te
c
te
d
b
y
N
G
S
in
ti
s
s
u
e
o
n
ly
(b
lu
e
),
p
la
s
m
a
o
n
ly
(l
ig
h
t
re
d
),
o
r
in
b
o
th
b
io
p
s
ie
s
(d
a
rk
re
d
).
a
D
e
n
o
te
s
S
N
V
in
c
tD
N
A
d
e
te
c
te
d
b
y
d
d
P
C
R
b
u
t
n
o
t
N
G
S
.
178 Molecular Oncology 13 (2019) 171–184 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Concordance of melanoma mutational landscape in tissue and ctDNA L. Calapre et al.
Fig. 2. Monitoring ctDNA levels in melanoma patients undergoing systemic therapy. Plasma ctDNA levels were determined using two
mutations and compared to FDG-PET metabolic tumor burden (MTB). Therapies are indicated by colored boxes. Disease status by
radiological imaging is indicated by arrows and labeled as PR: partial response, PD: progressive disease, or CR: complete response. For
patient MM475, PET scan images corresponding to clinical responses are shown above.
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These results indicate that well-known driver muta-
tions or infrequent deleterious mutations can be used
for ctDNA-based patient surveillance, given their close
correlation with changes in MTB.
3.5. TERT ctDNA is represented in lower levels in
plasma
Longitudinal monitoring of patients with detectable
TERT ctDNA (Fig. 2) revealed lower copies of these
mutations in plasma compared to that of other driver
mutations. In fact, of the 6 patients confirmed to harbor
TERT promoter mutations as well as another driver
mutation in their tumor tissue, TERT-mutated ctDNA
was underrepresented or undetectable in plasma relative
to the levels of the other mutation analyzed (Fig. 3A).
Given the location of these mutations within a promoter
region, we hypothesized that the underrepresentation of
TERT copies in plasma ctDNA is a result of low nucleo-
some occupancy at these sites, providing a lack of pro-
tection of this region against nuclease cleavage during
cell apoptosis (Ulz et al., 2016).
We therefore conducted in vitro experiments using
the melanoma cell lines 1205Lu and UACC62, which
are known to carry TERT promoter C228T and C250T
mutations, respectively, to determine whether similar
Fig. 3. Differential levels of promoter mutations in ctDNA. (A) Comparison of the TERT promoter mutations allelic frequency (AF) in tumor
tissue and copies per mL of plasma relative to the major driver mutation in six melanoma patients. (B–E) Bar graphs of the absolute copy
number of intragenic or promoter region of TERT in 1205Lu and UACC62 gDNA and supernatant ctDNA (B, C) or intragenic or promoter
region of DPH3 in C032 and A07 gDNA or supernatant ctDNA (D, E). Standard deviations of triplicate experiments are indicated. P values
≥0.05 (unpaired t-test) were considered as statistically significant.
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patterns of underrepresentation of the TERT promoter
regions are observed in the DNA isolated from the
supernatant of these cell lines. We found no difference
in the ratio of absolute copies of the intragenic TERT
and the promoter region in the genomic DNA of these
cells (Fig. 3B). However, there were significant differ-
ences in the copies of promoter TERT vs intragenic
TERT in supernatant-derived ctDNA for both cell lines
(P = 0.012), with more than fivefold less TERT pro-
moter copies compared intragenic TERT (Fig. 3C).
Recently, mutations in the DPH3 promoter region
have been found in 10% of melanomas (Denisova
et al., 2015). Given its location, we determined
whether the DPH3 promoter region is also underrepre-
sented in plasma. We screened our patient cohort for
DPH3 mutations, and similarly, we found underrepre-
sentation of this promoter mutation in the blood of
patient MM475 (Fig. 2). To further validate these find-
ings in vitro, we then tested the supernatant from A07
and C032 melanoma cell lines that were found to carry
the DPH3 C8T promoter mutation. We again found a
significantly lower number of absolute copies of DPH3
promoter compared to exonic DPH3 in the super-
natant cfDNA of A07 (P = 0.048) and C032
(P = 0.022) cell lines (Fig. 3D). The overall copies of
exonic and promoter regions of DPH3 were found at
approximately similar levels in genomic DNA from
the cells (Fig. 3E). Notably, these experiments high-
light the variability in representation of different loci
in cfDNA, which can impact the detection of promoter
region mutations in plasma ctDNA.
4. Discussion
Multiple studies over the last three years have provided
increasing evidence of the value of ctDNA for monitor-
ing treatment response in metastatic melanoma patients
(Ascierto et al., 2013; Girotti et al., 2016; Gray et al.,
2015; Knol et al., 2016; Schreuer et al., 2016) but mostly
relied on a few common driver mutations to determine
disease status for ctDNA analysis. Therefore, improved
methods that allow interrogation of multiple genes
together with further studies are required to determine
the concordance of genetic aberrations in matched tissue
and plasma biopsies in melanoma patients.
In this study, we validated a targeted sequencing
panel, comprised of 30 melanoma-associated genes, and
compared the mutation profiles in tumor tissue and
plasma across multiple patients prior to therapy com-
mencement. We demonstrated a high level of concor-
dance between tissue and plasma biopsies, supporting
the use of ctDNA as a suitable surrogate for genetic
profiling. We reported on the kinetics of ctDNA using
multiple targeted mutations within the same patient
throughout treatment response and disease progression.
Importantly, we provided clinical and in vitro evidence
of the underrepresentation in ctDNA of mutations in
promoter regions such as those of TERT and DPH3.
All these findings need to be considered for the clinical
implementation of ctDNA as a monitoring tool for mel-
anoma. Our results are of particular significance for
patients who are negative for BRAF mutations, as we
show that other mutations can be used for tumor moni-
toring.
Given the high mutational heterogeneity of mela-
noma tumors, the use of comprehensive and targeted
NGS technologies for molecular profiling proved
highly beneficial. With these, we characterized the
landscape of mutations in the tissue and peripheral
blood to identify molecular targets for patient surveil-
lance. Our panel was able to identify clinically relevant
somatic variants in 83% of patients, suggesting high
efficiency for identifying targetable mutations for lon-
gitudinal ctDNA monitoring.
We found a high proportion of metastatic mela-
noma patients had detectable ctDNA at baseline and
that genomic alterations in peripheral blood in
ctDNA-positive patients were highly concordant with
those in the tissue. We acknowledge that our conclu-
sions are based on a small sample size, including only
seven tissue and plasma ctDNA pairs for NGS analy-
sis. However, our results add to the mounting evidence
on the potential utility of ctDNA as a surrogate to
solid tumor biopsy and as an ideal candidate for
molecular analysis as previously demonstrated for vari-
ous cancers (Chae et al., 2017; Goldberg et al., 2018;
Jovelet et al., 2016; Murtaza et al., 2015; Wong et al.,
2017). Notably, we observed a bias towards ctDNA
detectability in patients with high metastatic burden.
Patients with an isolated metastasis, particularly in the
lymph nodes, consistently had no detectable ctDNA at
baseline, which constitutes a limitation to the use of
plasma ctDNA in the clinic (De Mattos-Arruda et al.,
2015; Li et al., 2016; Momtaz et al., 2016).
It is also important to note that we found few SNVs
in plasma only, which is in line with the idea that
ctDNA is representative of the sum of the multiple
tumor lesions and clones. While we did not assess the
mutational profile of multiple metastases, this result is
consistent with studies in melanoma and other cancers
detailing the capacity of ctDNA to comprehensively
capture tumor heterogeneity (Bettegowda et al., 2014;
FitzGerald et al., 2017; Murtaza et al., 2015; Wong
et al., 2017). Our results also highlighted high discor-
dance in the mutational profile of a patient with a large
gap between tissue and blood collection, suggesting
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potential impact of clonal evolution on the concordance
of tissue and plasma biopsies. Thus, changes in the
somatic mutational landscape, as part of disease evolu-
tion, must be taken in consideration when monitoring
cases where new metastases are inaccessible and selec-
tion of targetable mutations for monitoring melanoma
patients or treatment selection depends on the primary
tumor.
Notably, the kinetics of multiple ctDNA targets,
particularly melanoma driver mutations, uniformly
informed on tumor dynamics in response to treatment.
These results underscore the fact that well-known and/
or rare driver mutations can be used for ctDNA quan-
tification and patient surveillance. These findings are
in contrast to a previous study by Gremmel et al.
describing a case of mucosal melanoma with two dis-
tinct tumor subclones, identified by whole exome
sequencing, with differential response to imatinib,
chemotherapy, and immunotherapy (Gremel et al.,
2016). However, the use of a limited number of tar-
geted loci in our study may have constrained our abil-
ity to fully capture tumor heterogeneity. Another
limitation of our study is that only a single metastasis
was analyzed from each patient to obtain the muta-
tional data used for ctDNA surveillance. While the
ctDNA kinetics of driver mutations may be used to
determine systemic response to treatment, there is a
possibility that subclones prevalent in other metastases
may serve as a good indicator of the specific response
of individual metastatic deposits to therapy.
Significantly, our data call for caution when interpret-
ing ctDNA levels based on single locus analysis, particu-
larly in the context of promoter mutation targets.
Previous research has observed the presence of lower
copies of TERT ctDNA relative to other mutations
(McEvoy et al., 2017; Wong et al., 2017). Herein, we
also found a similar pattern of TERT and DPH3 pro-
moter underrepresentation in cell-free DNA in vivo and
in vitro. Ulz et al. (2016) previously reported that pro-
moters of transcriptionally active genes are often devoid
of nucleosomes and can induce variability in plasma
cfDNA. Thus, the biological process of cfDNA biogene-
sis may significantly affect quantitative-based applica-
tions for liquid biopsy, particularly for patient
monitoring. Nevertheless, as mutations in the TERT
promoter enhance TERT expression, which is associated
with poor disease-free and melanoma-specific survival
(Nagore et al., 2016), low levels of TERT promoter
mutation in cfDNA relative to other activating
mutations may be harnessed to delineate patients with
transcriptionally active TERT. Overall, our results
underscore the need for further studies into ctDNA biol-
ogy prior to its clinical implementation.
5. Conclusions
Overall, ctDNA has significant clinical value as a non-
invasive source of genetic material for mutational anal-
yses, which can guide treatment selection, and for
identification of traceable markers for patient monitor-
ing in melanoma. Its ease of access and relative ability
to accurately reflect disease burden make it a particu-
larly reliable biomarker for the surveillance of mela-
noma patients during treatment course.
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